These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34658958)

  • 1. Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments.
    Verdura E; Pérez-Cano L; Sabido-Vera R; Guney E; Hyvelin JM; Durham L; Gomez-Mancilla B
    Front Psychiatry; 2021; 12():722378. PubMed ID: 34658958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome.
    Pellerin D; Lortie A; Corbin F
    Platelets; 2018 Mar; 29(2):113-124. PubMed ID: 28660769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
    Berry-Kravis EM; Lindemann L; Jønch AE; Apostol G; Bear MF; Carpenter RL; Crawley JN; Curie A; Des Portes V; Hossain F; Gasparini F; Gomez-Mancilla B; Hessl D; Loth E; Scharf SH; Wang PP; Von Raison F; Hagerman R; Spooren W; Jacquemont S
    Nat Rev Drug Discov; 2018 Apr; 17(4):280-299. PubMed ID: 29217836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic Trade-Offs: Deciphering the Impact of Neurodiversity on Drug Development in Fragile X Syndrome.
    Bui TA; Shatto J; Cuppens T; Droit A; Bolduc FV
    Front Psychiatry; 2021; 12():730987. PubMed ID: 34733188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.
    Budimirovic DB; Berry-Kravis E; Erickson CA; Hall SS; Hessl D; Reiss AL; King MK; Abbeduto L; Kaufmann WE
    J Neurodev Disord; 2017; 9():14. PubMed ID: 28616097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced serum levels of pro-inflammatory chemokines in fragile X syndrome.
    Van Dijck A; Barbosa S; Bermudez-Martin P; Khalfallah O; Gilet C; Martinuzzi E; Elinck E; Kooy RF; Glaichenhaus N; Davidovic L
    BMC Neurol; 2020 Apr; 20(1):138. PubMed ID: 32295518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction.
    Telias M
    Curr Pharm Des; 2019; 25(41):4394-4404. PubMed ID: 31682210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensory Processing Phenotypes in Fragile X Syndrome.
    Rais M; Binder DK; Razak KA; Ethell IM
    ASN Neuro; 2018; 10():1759091418801092. PubMed ID: 30231625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.
    Gürkan CK; Hagerman RJ
    Res Autism Spectr Disord; 2012 Oct; 6(4):1311-1320. PubMed ID: 23162607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing our understanding of human cognition through the study of Fragile X Syndrome.
    Cook D; Nuro E; Murai KK
    Dev Neurobiol; 2014 Feb; 74(2):147-77. PubMed ID: 23723176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
    Lozano R; Hare EB; Hagerman RJ
    Neuropsychiatr Dis Treat; 2014; 10():1769-79. PubMed ID: 25258535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragile X syndrome: from targets to treatments.
    Wijetunge LS; Chattarji S; Wyllie DJ; Kind PC
    Neuropharmacology; 2013 May; 68():83-96. PubMed ID: 23257237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autism and fragile X syndrome.
    Yu TW; Berry-Kravis E
    Semin Neurol; 2014 Jul; 34(3):258-65. PubMed ID: 25192504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
    Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging pharmacologic treatment options for fragile X syndrome.
    Schaefer TL; Davenport MH; Erickson CA
    Appl Clin Genet; 2015; 8():75-93. PubMed ID: 25897255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenges of clinical trials in fragile X syndrome.
    Jacquemont S; Berry-Kravis E; Hagerman R; von Raison F; Gasparini F; Apostol G; Ufer M; Des Portes V; Gomez-Mancilla B
    Psychopharmacology (Berl); 2014 Mar; 231(6):1237-50. PubMed ID: 24173622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autism Symptoms in Fragile X Syndrome.
    Niu M; Han Y; Dy ABC; Du J; Jin H; Qin J; Zhang J; Li Q; Hagerman RJ
    J Child Neurol; 2017 Sep; 32(10):903-909. PubMed ID: 28617074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
    Baker EK; Arpone M; Aliaga SM; Bretherton L; Kraan CM; Bui M; Slater HR; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field M; Cohen J; Cornish K; Santa Maria L; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
    Mol Autism; 2019; 10():21. PubMed ID: 31073396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragile X syndrome: a review of clinical and molecular diagnoses.
    Ciaccio C; Fontana L; Milani D; Tabano S; Miozzo M; Esposito S
    Ital J Pediatr; 2017 Apr; 43(1):39. PubMed ID: 28420439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.